Trials / Completed
CompletedNCT02842333
Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses. The aim of this prospective preliminary study is to evaluate the presence of UCP-specific Th1 responses in patients in complete remission of CML two years after end of Tyrosine Kinase Inhibitor (TKi) treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Additional biological samples | Blood samples |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-10-06
- Completion
- 2020-10-06
- First posted
- 2016-07-22
- Last updated
- 2025-05-25
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02842333. Inclusion in this directory is not an endorsement.